Bavarian Nordic A/S (BAVA.CO)
DKK 198.95
(2.82%)
DKK 198.95
(2.82%)
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2023 | 15.13 Million DKK | -97.59% |
| 2022 | 629.26 Million DKK | 165.56% |
| 2021 | 236.95 Million DKK | -47.05% |
| 2020 | 447.46 Million DKK | 1.01% |
| 2019 | 442.99 Million DKK | 11.41% |
| 2018 | 397.61 Million DKK | -0.54% |
| 2017 | 399.76 Million DKK | 1245.36% |
| 2016 | 29.71 Million DKK | -5.14% |
| 2015 | 31.32 Million DKK | -5.91% |
| 2014 | 33.29 Million DKK | -53.65% |
| 2013 | 71.83 Million DKK | 94.25% |
| 2012 | 36.98 Million DKK | -58.98% |
| 2011 | 90.15 Million DKK | -7.82% |
| 2010 | 97.8 Million DKK | 0.0% |
| 2009 | - DKK | 0.0% |
| 2008 | - DKK | -100.0% |
| 2007 | 134.67 Million DKK | -9.6% |
| 2006 | 148.97 Million DKK | -28.35% |
| 2005 | 207.91 Million DKK | 0.0% |
| 2004 | - DKK | 0.0% |
| 2003 | - DKK | 0.0% |
| 2002 | - DKK | 0.0% |
| 2001 | - DKK | 0.0% |
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2024 Q2 | 14.18 Million DKK | -3.25% |
| 2024 Q1 | 14.66 Million DKK | -3.11% |
| 2023 Q4 | 15.13 Million DKK | -77.26% |
| 2023 Q2 | 882.16 Million DKK | 24.71% |
| 2023 Q1 | 707.35 Million DKK | 12.41% |
| 2023 FY | 15.13 Million DKK | -97.59% |
| 2023 Q3 | 66.54 Million DKK | -92.46% |
| 2022 Q1 | 75.73 Million DKK | -68.04% |
| 2022 FY | 629.26 Million DKK | 165.56% |
| 2022 Q4 | 629.26 Million DKK | -0.34% |
| 2022 Q3 | 631.42 Million DKK | 14.23% |
| 2022 Q2 | 552.78 Million DKK | 629.9% |
| 2021 Q3 | 80.57 Million DKK | -82.38% |
| 2021 Q1 | 462.2 Million DKK | 3.29% |
| 2021 Q2 | 457.38 Million DKK | -1.04% |
| 2021 FY | 236.95 Million DKK | -47.05% |
| 2021 Q4 | 236.95 Million DKK | 194.09% |
| 2020 Q4 | 447.46 Million DKK | -1.46% |
| 2020 FY | 447.46 Million DKK | 1.01% |
| 2020 Q1 | 469.13 Million DKK | 5.9% |
| 2020 Q2 | 466.15 Million DKK | -0.64% |
| 2020 Q3 | 454.08 Million DKK | -2.59% |
| 2019 Q2 | 448.49 Million DKK | -0.82% |
| 2019 Q4 | 442.99 Million DKK | -0.42% |
| 2019 Q3 | 444.83 Million DKK | -0.81% |
| 2019 FY | 442.99 Million DKK | 11.41% |
| 2019 Q1 | 452.2 Million DKK | 13.73% |
| 2018 Q1 | 399.22 Million DKK | -0.13% |
| 2018 Q3 | 398.14 Million DKK | -0.13% |
| 2018 Q4 | 397.61 Million DKK | -0.13% |
| 2018 FY | 397.61 Million DKK | -0.54% |
| 2018 Q2 | 398.68 Million DKK | -0.13% |
| 2017 Q2 | 28.65 Million DKK | -1.82% |
| 2017 Q4 | 399.76 Million DKK | 1321.82% |
| 2017 FY | 399.76 Million DKK | 1245.36% |
| 2017 Q1 | 29.18 Million DKK | -1.79% |
| 2017 Q3 | 28.11 Million DKK | -1.86% |
| 2016 Q3 | 30.37 Million DKK | 0.28% |
| 2016 FY | 29.71 Million DKK | -5.14% |
| 2016 Q4 | 29.71 Million DKK | -2.19% |
| 2016 Q2 | 30.29 Million DKK | -1.67% |
| 2016 Q1 | 30.8 Million DKK | -1.64% |
| 2015 Q4 | 31.32 Million DKK | -1.55% |
| 2015 Q1 | 32.8 Million DKK | -1.48% |
| 2015 Q2 | 32.3 Million DKK | -1.52% |
| 2015 FY | 31.32 Million DKK | -5.91% |
| 2015 Q3 | 31.81 Million DKK | -1.5% |
| 2014 FY | 33.29 Million DKK | -53.65% |
| 2014 Q1 | 69.7 Million DKK | -2.97% |
| 2014 Q2 | 67.9 Million DKK | -2.58% |
| 2014 Q3 | 75.2 Million DKK | 10.75% |
| 2014 Q4 | 33.29 Million DKK | -55.73% |
| 2013 Q3 | 74.5 Million DKK | -2.23% |
| 2013 FY | 71.83 Million DKK | 94.25% |
| 2013 Q1 | 36.6 Million DKK | -1.03% |
| 2013 Q2 | 76.2 Million DKK | 108.2% |
| 2013 Q4 | 71.83 Million DKK | -3.58% |
| 2012 Q1 | 86.4 Million DKK | -4.16% |
| 2012 Q4 | 36.98 Million DKK | -55.76% |
| 2012 Q3 | 83.6 Million DKK | -3.91% |
| 2012 FY | 36.98 Million DKK | -58.98% |
| 2012 Q2 | 87 Million DKK | 0.69% |
| 2011 Q2 | 89.1 Million DKK | -3.15% |
| 2011 Q1 | 92 Million DKK | -5.93% |
| 2011 Q4 | 90.15 Million DKK | -0.16% |
| 2011 Q3 | 90.3 Million DKK | 1.35% |
| 2011 FY | 90.15 Million DKK | -7.82% |
| 2010 Q1 | 102.8 Million DKK | 0.0% |
| 2010 Q4 | 97.8 Million DKK | -0.61% |
| 2010 Q3 | 98.4 Million DKK | -8.21% |
| 2010 FY | 97.8 Million DKK | 0.0% |
| 2010 Q2 | 107.2 Million DKK | 4.28% |
| 2009 Q4 | - DKK | 0.0% |
| 2009 FY | - DKK | 0.0% |
| 2008 FY | - DKK | -100.0% |
| 2007 FY | 134.67 Million DKK | -9.6% |
| 2006 FY | 148.97 Million DKK | -28.35% |
| 2005 FY | 207.91 Million DKK | 0.0% |
| 2004 FY | - DKK | 0.0% |
| 2003 FY | - DKK | 0.0% |
| 2002 FY | - DKK | 0.0% |
| 2001 FY | - DKK | 0.0% |
| Name | Long Term Debt | Long Term Debt Difference |
|---|---|---|
| ALK-Abelló A/S | 439 Million DKK | 96.552% |
| Genmab A/S | 680 Million DKK | 97.774% |
| Gubra A/S | 60.68 Million DKK | 75.06% |
| Novo Nordisk A/S | 20.52 Billion DKK | 99.926% |
| Orphazyme A/S | - DKK | -Infinity% |
| Pharma Equity Group A/S | 8.07 Million DKK | -87.5% |
| Zealand Pharma A/S | 102.57 Million DKK | 85.245% |